STIM1 promotes acquired resistance to sorafenib by attenuating ferroptosis in hepatocellular carcinoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

STIM1 promotes acquired resistance to sorafenib by attenuating ferroptosis in hepatocellular carcinoma

Published:2024-11 Issue:6 Volume:11 Page:101281
ISSN:2352-3042
Container-title:Genes & Diseases
language:en
Short-container-title:Genes & Diseases

Author:

Ren Ran,Chen Yu,Zhou Yu^ORCID,Shen Luyao,Chen Yang^ORCID,Lei Juan,Wang Jingchun,Liu Xudong,Zhang Nan,Zhou Dongqin,Zhao Huakan^ORCID,Li Yongsheng

Funder

NSFC

Publisher

Elsevier BV

Reference44 articles.

1. Cancer statistics, 2022;Siegel;CA A Cancer J Clin,2022

2. Targeted therapy for hepatocellular carcinoma;Huang;Signal Transduct Targeted Ther,2020

3. Strategies to improve the antitumor effect of immunotherapy for hepatocellular carcinoma;Xing;Front Immunol,2021

4. Combination of NK-based immunotherapy and sorafenib against hepatocellular carcinoma;Yang;Am J Cancer Res,2021

5. The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects;Tang;Signal Transduct Targeted Ther,2020

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP